CRIS Current Research Information System

TAVOLARI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.118
NA - Nord America 3.882
EU - Europa 2.500
AF - Africa 271
SA - Sud America 171
OC - Oceania 4
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.948
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.835
CN - Cina 1.111
SG - Singapore 1.110
VN - Vietnam 1.085
GB - Regno Unito 449
IT - Italia 418
SE - Svezia 329
DE - Germania 295
HK - Hong Kong 219
FR - Francia 174
IN - India 161
KR - Corea 143
CH - Svizzera 135
IE - Irlanda 132
BR - Brasile 106
FI - Finlandia 100
RU - Federazione Russa 99
NL - Olanda 93
UA - Ucraina 81
CI - Costa d'Avorio 63
ZA - Sudafrica 56
TG - Togo 55
JP - Giappone 52
SC - Seychelles 51
JO - Giordania 38
BE - Belgio 34
CA - Canada 33
ID - Indonesia 30
PH - Filippine 30
NG - Nigeria 28
EE - Estonia 26
BG - Bulgaria 24
AT - Austria 20
AR - Argentina 19
PL - Polonia 18
TH - Thailandia 18
TR - Turchia 16
CL - Cile 13
IQ - Iraq 13
BD - Bangladesh 12
GR - Grecia 12
TW - Taiwan 12
EC - Ecuador 11
HR - Croazia 11
PK - Pakistan 11
SA - Arabia Saudita 11
ES - Italia 10
LT - Lituania 8
MY - Malesia 8
RO - Romania 8
UZ - Uzbekistan 8
IR - Iran 7
MX - Messico 7
PS - Palestinian Territory 7
CO - Colombia 6
PE - Perù 5
PT - Portogallo 5
AU - Australia 4
PY - Paraguay 4
TN - Tunisia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
SI - Slovenia 3
EG - Egitto 2
HU - Ungheria 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
MT - Malta 2
NP - Nepal 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GF - Guiana Francese 1
GH - Ghana 1
GI - Gibilterra 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
MC - Monaco 1
NE - Niger 1
PA - Panama 1
Totale 10.946
Salva come PNG Salva come JPEG
Città #
Singapore 797
Ashburn 398
Chandler 379
Southend 369
Hefei 329
Dallas 294
Ho Chi Minh City 258
Fairfield 245
Dong Ket 213
Hanoi 208
Hong Kong 205
San Jose 199
Houston 152
Santa Clara 150
Bologna 136
Dublin 132
Seoul 128
Bern 125
Beijing 121
Princeton 115
Wilmington 115
Ann Arbor 108
Woodbridge 108
Seattle 99
Boardman 91
Cambridge 90
Helsinki 81
New York 70
Abidjan 63
Council Bluffs 62
Lauterbourg 62
Lomé 55
Los Angeles 49
Frankfurt am Main 47
Jacksonville 47
Tokyo 45
Nanjing 43
Da Nang 40
Westminster 38
Amman 36
Berlin 34
Bengaluru 33
Milan 33
Brussels 31
Haiphong 31
Padova 30
Buffalo 28
Guangzhou 28
Redondo Beach 28
Jinan 27
Redmond 26
Rome 26
San Diego 25
Sofia 24
Jakarta 23
Shanghai 22
London 19
Medford 18
Abeokuta 17
Johannesburg 17
Shenyang 17
São Paulo 16
Munich 15
Changsha 14
Chicago 14
Lappeenranta 14
Mülheim 14
Toronto 14
Turin 14
Zhengzhou 14
Can Tho 13
Quận Ba 13
The Dalles 13
Tongling 13
Biên Hòa 12
Florence 12
Hebei 12
Nanchang 12
Orem 12
Phoenix 12
San Francisco 12
Vienna 12
Amsterdam 11
Fremont 11
Jiaxing 11
Montreal 11
Warsaw 11
Des Moines 10
Kuban 10
Nuremberg 10
Saint Petersburg 10
Hải Dương 9
Olalla 9
Shenzhen 9
Bühl 8
Dearborn 8
Norwalk 8
Redwood City 8
Thái Nguyên 8
Tianjin 8
Totale 7.286
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment in biliary tract cancer 341
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 301
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 248
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 246
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 246
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 238
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 236
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 225
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 216
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 216
Simple and dendritic cyclam derivative. Photophysical properties, effect of protonation and Zn++ coordination, preliminary screening as inhibitors of tumor cell growth 213
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 204
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 203
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. 202
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 200
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 198
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland 198
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 197
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 195
Angiogenesis modulation in human umbilical endothelial vein (HUVE) cells by selected polychlorobiphenyls congeners is mediated by estrogen receptor alpha (ERα) binding. 195
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 194
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 191
In Reply 188
Selected polychlorobiphenyls congeners bind to estrogen receptor alpha in human umbilical vascular endothelial (HUVE) cells modulating angiogenesis 179
The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. 178
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 175
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 174
Annellated pyrrole compounds for cancer management 173
Cholangiocarcinoma: Epidemiology and risk factors 173
Immunomodulation by 17beta-estradiol in bivalve hemocytes. 169
Annellated pyrrole compounds for cancer management 169
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner 169
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression 168
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 166
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 164
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 163
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 161
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 156
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 153
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 149
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link 148
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 145
Genomic And Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors 143
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. 141
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 140
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice 139
IN VIVO/IN VITRO AGED FIBROBLASTS TRIGGER MALIGNANT FEATURES IN NORMAL AND CANCER STEM/PROGENITOR CELLS OF THE MAMMARY GLAND 139
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 133
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 130
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 125
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 122
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 117
The protease inhibitor gabexate Mesylate has antitumor effects and enhances gemcitabine action on pancreatic cancer cell lines 112
Carcinogenesis of Cholangiocarcinoma 110
Asbestos and Intrahepatic Cholangiocarcinoma 110
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 106
Evolution of the experimental models of cholangiocarcinoma 105
TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells 102
Nivolumab: an investigational agent for the treatment of biliary tract cancer 101
null 99
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. 89
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma 88
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 88
Have We Found the “Holy Grail” That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? 84
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. 82
Current and novel therapeutic opportunities for systemic therapy in biliary cancer 72
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 61
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 22
Totale 11.190
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.924
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.924
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021316 0 0 0 0 0 0 0 0 0 36 35 245
2021/20221.143 100 35 63 83 75 39 26 57 109 95 234 227
2022/20231.586 166 232 91 186 99 108 31 99 250 41 103 180
2023/2024422 54 59 22 34 34 97 14 25 10 31 15 27
2024/20251.666 70 209 163 122 199 82 112 51 30 139 133 356
2025/20264.287 430 558 586 341 427 226 520 158 765 276 0 0
Totale 11.190